Alyeska Investment Group
STOK icon

Alyeska Investment Group’s Stoke Therapeutics STOK Stock Holding History

Alyeska Investment Group’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-75,000
Closed -$2.38M – 740
2025
Q4 		$2.38M Buy
+75,000
New +$2.25M 0.01% 513
2019
Q3 		– Sell
-50,167
Closed -$1.46M – 487
2019
Q2 		$1.46M Buy
+50,167
New +$1.35M 0.02% 348

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Alyeska Investment Group's STOK Position: Q1 2026 in Review

Alyeska Investment Group sold out of Stoke Therapeutics (STOK) in Q1 2026, closing a stake of 75,000 shares — an estimated $2.38M sold.

Alyeska Investment Group first reported a position in STOK in Q2 2019 and held it in 2 quarters. The position peaked at $2.38M in Q4 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Alyeska Investment Group reported no remaining Stoke Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Alyeska Investment Group sold 75,000 Stoke Therapeutics shares in Q1 2026, an estimated $2.38M.
  • Alyeska Investment Group first reported a position in Stoke Therapeutics in Q2 2019 and held it in 2 quarters.
  • Alyeska Investment Group's Stoke Therapeutics position peaked at $2.38M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.